CSBio CSBio

X
[{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo US$ 55M Series A Generation Therapeutics for BleedingThrombosis Disorders","therapeuticArea":"Hematology","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Hemab Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Proceeds from the financing will be used to progress the Company's promising pipeline of monoclonal and bispecific antibody-based therapeutics into later stages of development.

            Lead Product(s): Monoclonal-bispecific Antibody-based Therapeutics

            Therapeutic Area: Hematology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Novo Nordisk

            Deal Size: $55.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing July 22, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY